Your shopping cart is currently empty

PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $30 | - | In Stock | |
| 5 mg | $88 | - | In Stock | |
| 10 mg | $148 | - | In Stock | |
| 25 mg | $251 | - | In Stock | |
| 50 mg | $358 | - | In Stock | |
| 100 mg | $518 | - | In Stock | |
| 200 mg | $715 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $141 | - | In Stock |
| Description | PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist. |
| In vivo | SCID mice demonstrate a markedly enhanced abdominal response to colorectal distension (CRD), with distension levels ranging from 0.04 to 0.1 mL amplifying the intensity of the EMG response from 384% to 132%, respectively, as compared to BALB/cBy controls (P<0.01; P<0.01; P<0.01; P<0.001). Activation of PAR-4 significantly mitigates this hypersensitivity (P<0.01, P<0.05; P<0.05; P<0.05)[1]. |
| Synonyms | PAR-4-AP (TFA), AY-NH2 (TFA) |
| Molecular Weight | 794.82 |
| Formula | C36H49F3N8O9 |
| Cas No. | 1228078-65-6 |
| Smiles | OC(=O)C(F)(F)F.C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O |
| Relative Density. | no data available |
| Sequence | Ala-Tyr-Pro-Gly-Lys-Phe-NH2 |
| Sequence Short | AYPGKF |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 100 mg/mL (125.81 mM), Sonication is recommended. DMSO: 250 mg/mL (314.54 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (6.29 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.